Tolvaptan reduces angiotensin II-induced experimental abdominal aortic aneurysm and dissection.
Sign Up to like & getrecommendations! Published in 2022 at "Vascular pharmacology"
DOI: 10.1016/j.vph.2022.106973
Abstract: Tolvaptan has been approved for the treatment of autosomal dominant polycystic kidney disease and heart failure. However, the role of tolvaptan in patients with abdominal aortic aneurysm (AAA) has not been examined. Human aortic smooth… read more here.
Keywords: tolvaptan; abdominal aortic; dissection; tolvaptan reduces ... See more keywords